Hypoglycaemic episodes in patients with type 2 diabetes - risk factors andassociations with patient-reported outcomes: The PANORAMA Study

Diabetes and Metabolism

Volumn 41, Issue 6, 2015, Pages 470-479

  Simon, D ^a   de Pablos Velasco, P ^b   Parhofer, K G ^c   Gonder Frederick L ^d   Lomon, I Duprat ^e   Vandenberghe, H ^f   Eschwege E ^g   Bradley, C ^h  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f ASTRAZENECA   (United Kingdom)

^g CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^h UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Glucose lowering treatments; Hypoglycaemia; Patient reported outcomes; Quality of life; Type 2 diabetes

Indexed keywords

INSULIN; ANTIDIABETIC AGENT;

AGED; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SATISFACTION; VISUAL ANALOG SCALE; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; TREATMENT OUTCOME;

AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84975645794     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.08.007     Document Type: Article

References (40)

1. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA,et al. The association between symptomatic, severe hypoglycaemia andmortality in type 2 diabetes: retrospective epidemiological analysis of theACCORD study. BMJ 2010;340:b4909.
2. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact ofnon-severe hypoglycemic events on work productivity and diabetes man-agement. Value Health 2011;14:665-71.
3. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hos-pitalizations for adverse drug events in older Americans. N Engl J Med2011;365:2002-12.
4. Riddle MC, Karl DM. Individualizing targets and tactics for high-riskpatients with type 2 diabetes: practical lessons from ACCORD and othercardiovascular trials. Diabetes Care 2012;35:2100-7.
5. Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, RyanGJ, et al. National estimates of insulin-related hypoglycemia and errorsleading to emergency department visits and hospitalizations. JAMA InternMed 2014;174:678-86.
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M,et al. Management of hyperglycemia in type 2 diabetes: a patient-centeredapproach: position statement of the American Diabetes Association (ADA)and the European Association for the Study of Diabetes (EASD). DiabetesCare 2012;35:1364-79.
7. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in peoplewith diabetes. Diabet Med 2001;18:690-705.
8. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypo-glycemia and cardiac ischemia: a study based on continuous monitoring.Diabetes Care 2003;26:1485-9.
9. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, et al.Risk of cardiac arrhythmias during hypoglycemia in patients with type 2diabetes and cardiovascular risk. Diabetes 2014;63:1738-47.
10. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascularrisks. Diabetes Care 2011;34(Suppl. 2):S132-7.
11. Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associ-ated with antihyperglycemic medications on vascular risks in veterans withtype 2 diabetes. Diabetes Care 2012;35:1126-32.
12. Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the"dead-in-bed" syndrome, as captured by a retrospective continuous glucosemonitoring system. Endocr Pract 2010;16:244-8.
13. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD andADVANCE trials. N Engl J Med 2008;358:2630-3.
14. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff Jr DC,et al. Long-term effects of intensive glucose lowering on cardiovascularoutcomes. N Engl J Med 2011;364:818-28.
15. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 dia-betes. Diabet Med 2008;25:245-54.
16. UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2diabetic patients is affected by complications but not by intensive policiesto improve blood glucose or blood pressure control (UKPDS 37). DiabetesCare 1999;22:1125-36.
17. de Pablos-Velasco P, Parhofer KG, Bradley C, Eschwège E, Gönder-Frederick L, Maheux P, et al. Current level of glycemic control and itsassociated factors in patients with type 2 diabetes across Europe: data fromthe PANORAMA study. Clin Endocrinol 2014;80:47-56.
18. Bradley C, de Pablos-Velasco P, Parhofer KG, Eschwege E, Gonder-Frederick L, Simon D. PANORAMA: a European study to evaluate qualityof life and treatment satisfaction in patients with type-2 diabetes mellitus-study design. Prim Care Diabetes 2011;5:231-9.
19. National Glycohemoglobin Standardization Program. List of NGSPcertified methods; 2014 cited 2014 Jun 27 http://www ngsp org/docs/methods pdf.
20. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. Thedevelopment of an individualized questionnaire measure of perceivedimpact of diabetes on quality of life: the ADDQoL. Qual Life Res1999;8:79-91.
21. Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: report of a Working Group of the World Health OrganizationRegional Office for Europe and International Diabetes Federation EuropeanRegion St Vincent Declaration Action Programme for Diabetes. DiabetMed 1994;11:510-6.
22. Gonder-Frederick LA, Schmidt KM, Vajda KA, Greear ML, SinghH, Shepard JA, et al. Psychometric properties of the hypoglycemiafear survey-II for adults with type 1 diabetes. Diabetes Care 2011;34:801-6.
23. EuroQoL group. EuroQol -a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
24. DCCT Research Group. Hypoglycemia in the diabetes control andcomplications trial. The Diabetes Control and Complications TrialResearch Group. Diabetes 1997;46:271-86.
25. Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer CD, WitteDR, et al. Severe hypoglycemia and cardiovascular disease incidence intype 1 diabetes: the EURODIAB prospective complications study. DiabetesCare 2012;35:1598-604.
26. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia inpatients with type 2 diabetes treated with a combination of metformin andsulphonylurea therapy in France. Diabetes Obes Metab 2008;10(Suppl.1):16-24.
27. Tschope D, Bramlage P, Binz C, Krekler M, Plate T, Deeg E, et al. Antidi-abetic pharmacotherapy and anamnestic hypoglycemia in a large cohort oftype 2 diabetic patients -an analysis of the DiaRegis registry. CardiovascDiabetol 2011;10:66.
28. Lipska KJ, Warton EM, Huang ES, Moffet HH, Inzucchi SE, KrumholzHM, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: thediabetes and aging study. Diabetes Care 2013;36:3535-42.
29. Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holle-man F. The incidence of mild and severe hypoglycaemia in patients withtype 2 diabetes mellitus treated with sulfonylureas: a systematic review andmeta-analysis. Diabetes Metab Res Rev 2014;30:11-22.
30. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al.Frequency of severe hypoglycemia requiring emergency treatment in type1 and type 2 diabetes: a population-based study of health service resourceuse. Diabetes Care 2003;26:1176-80.
31. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, Lyu R, Mavros P,Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence andtheir associations with glycaemic goal in patients with type 2 diabetes mel-litus: findings from the real-life effectiveness and care patterns of diabetesmanagement (RECAP-DM) study. Diabetes Obes Metab 2008;10(Suppl.1):25-32.
32. Alvarez-Guisasola F, Yin DD, Nocea G, Qiu Y, Mavros P. Association ofhypoglycemic symptoms with patients' rating of their health-related qualityof life state: a cross sectional study. Health Qual Life Outcomes 2010;8:86.
33. Pettersson B, Rosenqvist U, Deleskog A, Journath G, Wandell P. Self-reported experience of hypoglycemia among adults with type 2 diabetesmellitus (Exhype). Diabetes Res Clin Pract 2011;92:19-25.
34. Moses R. A review of clinical experience with the prandial glucoseregulator, repaglinide, in the treatment of type 2 diabetes. Expert OpinPharmacother 2000;1:1455-67.
35. Guardado-Mendoza R, Prioletta A, Jimenez-Ceja LM, Sosale A, FolliF. The role of nateglinide and repaglinide, derivatives of meglitinide,in the treatment of type 2 diabetes mellitus. Arch Med Sci 2013;9:936-43.
36. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidi-abetic drugs added to metformin therapy on glycemic control, weight gain,and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-8.
37. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk ofsevere hypoglycaemia: post hoc epidemiological analysis of the ACCORDstudy. BMJ 2010;340:b5444.
38. Inkster B, Riha RL, Van Look L, Williamson R, McLachlan S, Frier BM,et al. Association between excessive daytime sleepiness and severe hypo-glycemia in people with type 2 diabetes: the Edinburgh type 2 diabetesstudy. Diabetes Care 2013;36:4157-9.
39. Ndong JR, Romon I, Druet C, Prévot L, Hubert-Brierre R, Pascolini E,et al. Caractéristiques, risque vasculaire, complications et qualité des soinsdes personnes diabétiques dans les départements d'outre-mer et comparai-son à la métropole: ENTRED 2007-2010, France. Bull Epidemiol Hebd2010;42-43:432-6.
40. Lee SJ. So much insulin, so much hypoglycemia. JAMA Intern Med2014;174:686-8.